Taken together, these data indicate that concurrent TP53 mutations and EGFR amplifications that are known to affect the prognosis of patients with EGFR-mutant NSCLC did not affect the survival outcomes of EGFR-TKI plus crizotinib combination therapy. Here, TP53 is linked to non-small cell lung carcinoma.